Citadel Advisors’s Vor Biopharma VOR Stock Holding History

Citadel Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,725	Closed	-$166K	–	14334
2025 Q4	$166K	Buy	12,725 +8,205	+182%	+$153K	﹤0.01%	11202
2025 Q3	$220K	Buy	+4,520	New	+$182K	﹤0.01%	11059
2025 Q1	–	Sell	-105	Closed	-$2.33K	–	15651
2024 Q4	$2.33K	Buy	105 +100	+2,000%	+$1.66K	﹤0.01%	14096
2024 Q3	$70	Buy	+5	New	+$91	﹤0.01%	14095
2024 Q2	–	Sell	-5	Closed	-$237	–	15497
2024 Q1	$237	Buy	+5	New	+$220	﹤0.01%	14383
2023 Q4	–	Sell	-170	Closed	-$7.21K	–	15330
2023 Q3	$7.21K	Sell	170 -50	-23%	-$2.71K	﹤0.01%	13272
2023 Q2	$13.6K	Buy	220 +160	+267%	+$14.6K	﹤0.01%	13032
2023 Q1	$6.46K	Sell	60 -5	-8%	-$554	﹤0.01%	13805
2022 Q4	$8.64K	Buy	+65	New	+$6.43K	﹤0.01%	13737

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors's VOR Position: Q2 2026 in Review

Citadel Advisors increased its Vor Biopharma (VOR) stake by 7.8% in Q2 2026, buying an estimated $176K and bringing the position to 160,414 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #5731.

Citadel Advisors first reported a position in VOR in Q4 2021 and has held it in 17 quarters since. The position peaked at $5.68M in Q4 2025. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Citadel Advisors held 160,414 shares of Vor Biopharma worth $2.95M as of Q2 2026.
Citadel Advisors bought 11,646 Vor Biopharma shares in Q2 2026, an estimated $176K.
Vor Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5731 holding.
Citadel Advisors first reported a position in Vor Biopharma in Q4 2021 and has held it in 17 quarters since.
Citadel Advisors's Vor Biopharma position peaked at $5.68M in Q4 2025.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.